Because the frequency of HLA-DR53-linked HLA-DR alleles has been reported to be 39% in the HNSCC patients12, these results indicate that peptide HER-3872−886 is able to elicit CD4 responses in broad population of HNSCC patients. Here, CD4 is linked to head and neck squamous cell carcinoma.